8-K ·Filed Jun 3, 2026

IQV

IQVIA HOLDINGS INC.
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago SEC0001193125-26-255635
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

This is a liability management exercise — extending maturities with no change to net debt. Monitor the final coupon spread relative to IQVIA's existing credit curve for any signal on credit quality. No immediate equity impact.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
IQV ▲ +39.97% at T+60d
NEUTRAL call ✓ call won +39.97% · α vs SPY +38.35% · entry $186.85 → $261.54
Entry anchored
Jun 3, 2026
via day open
T+1d
-1.88%
call -1.88% · α +0.71%
$183.33
settled 4mo ago
T+5d
-3.10%
call -3.10% · α -0.54%
$181.06
settled 4mo ago
T+20d
+10.81%
call +10.81% · α +12.43%
$207.04
settled 3mo ago
T+60d
+39.97%
call +39.97% · α +38.35%
$261.54
settled 5w ago

Price Chart

Loading chart...

Executive Summary

IQVIA announced that its wholly owned subsidiary intends to raise €950 million through an offering of senior notes due 2033, with proceeds used to refinance existing indebtedness and pay related fees. This is a routine debt refinancing that extends maturities without changing the company's overall leverage profile materially.

Key Facts

  • IQVIA Inc. intends to raise €950,000,000 in gross proceeds via senior notes due 2033.
  • Proceeds will be used to refinance certain existing indebtedness and pay fees/expenses.
  • The offering is subject to market and other customary conditions.
  • Notes are being offered only to QIBs under Rule 144A and non-U.S. investors under Regulation S.
  • No registration under the Securities Act — private placement.

Financial Impact

€950 million senior note offering to refinance existing debt; no new net debt added.

debtinterest expense

Risk Factors

  • If market conditions deteriorate, the offering may not close or may close at unfavorable terms.
  • Higher interest rate environment could increase interest expense if new notes carry a higher coupon than refinanced debt.

Market Snapshot

Exchange
NYSE
Sector
Services-Commercial Physical & Biological Research
Analyst Consensus
80% bullish (30 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-255635
Document: d42817dex991.htm0001193125-26-255635
Document: 0001193125-26-255635-index-headers.html0001193125-26-255635
Document: 0001193125-26-255635-index.html0001193125-26-255635
Document: 0001193125-26-255635.txt0001193125-26-255635
9 reports for IQV
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for IQV — sortable, filterable
TypeNow
Aug 4, 2026
8w ago
Insider Cluster
NEUTRAL ★ 4/10
$236.05 $263.84▲ +11.77%▲ +12.37%$257.29 (+9.00%)
Jul 31, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$233.36 $260.37▲ +11.57%▲ +10.33%$257.29 (+10.25%)
Jul 28, 2026
9w ago
8-K
BULLISH ★ 7/10
$242.94 $259.42▲ +6.78%▲ +3.40%$257.29 (+5.91%)
Jun 11, 2026
16w ago
8-K
NEUTRAL ★ 3/10
$181.46 $207.85▲ +14.54%▲ +12.76%$257.29 (+41.79%)
Jun 4, 2026
17w ago
8-K
NEUTRAL ★ 3/10
$183.45 $205.97▲ +12.28%▲ +10.41%$257.29 (+40.25%)
Jun 3, 2026
17w ago
8-K
NEUTRAL ★ 3/10
$186.85 $207.04▲ +10.81%▲ +12.43%$257.29 (+37.70%)
Mar 30, 2026
26w ago
Court Ruling
NEUTRAL ★ 1/10
$166.16 $158.98▼ −4.32%▼ −16.94%$257.29 (+54.84%)
Mar 17, 2026
28w ago
Court Ruling
BULLISH ★ 6/10
$168.43 $178.10▲ +5.74%▲ +1.40%$257.29 (+52.76%)
Feb 27, 2026
30w ago
DEFA14A
NEUTRAL ★ 3/10
$174.24 $166.02▼ −4.72%▲ +3.22%$257.29 (+47.67%)
Showing 9 of 9

US Market Status

Market Open — Closes in 3h 14m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access